PANEPOPHENANTHRIN

ID: ALA519800

Max Phase: Preclinical

Molecular Formula: C22H28O8

Molecular Weight: 420.46

Molecule Type: Small molecule

Associated Items:

Representations

Synonyms (1): Panepophenanthrin
Synonyms from Alternative Forms(1):

    Canonical SMILES:  CC(C)(O)/C=C/[C@@]12[C@H]3[C@@H](O)[C@@H]4O[C@@H]4[C@]1(O)OC(C)(C)[C@@H]2C=C1C(=O)[C@H]2O[C@H]2[C@H](O)[C@H]13

    Standard InChI:  InChI=1S/C22H28O8/c1-19(2,26)5-6-21-9-7-8-10(13(24)16-15(28-16)12(8)23)11(21)14(25)17-18(29-17)22(21,27)30-20(9,3)4/h5-7,9-11,13-18,24-27H,1-4H3/b6-5+/t9-,10+,11+,13+,14+,15+,16-,17-,18-,21+,22-/m0/s1

    Standard InChI Key:  WQBRQZUREPTGLI-MMNRQHNKSA-N

    Associated Targets(Human)

    Ubiquitin-like modifier-activating enzyme 1 57 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Molecule Features

    Natural Product: NoOral: NoChemical Probe: NoParenteral: No
    Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
    Chirality: NoAvailability: NoProdrug: No

    Drug Indications

    MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

    Mechanisms of Action

    Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

    Properties

    Molecular Weight: 420.46Molecular Weight (Monoisotopic): 420.1784AlogP: -0.56#Rotatable Bonds: 2
    Polar Surface Area: 132.28Molecular Species: NEUTRALHBA: 8HBD: 4
    #RO5 Violations: 0HBA (Lipinski): 8HBD (Lipinski): 4#RO5 Violations (Lipinski): 0
    CX Acidic pKa: 10.60CX Basic pKa: CX LogP: -0.56CX LogD: -0.56
    Aromatic Rings: 0Heavy Atoms: 30QED Weighted: 0.35Np Likeness Score: 3.24

    References

    1. Sekizawa R, Ikeno S, Nakamura H, Naganawa H, Matsui S, Iinuma H, Takeuchi T..  (2002)  Panepophenanthrin, from a mushroom strain, a novel inhibitor of the ubiquitin-activating enzyme.,  65  (10): [PMID:12398550] [10.1021/np020098q]
    2. da Silva SR, Paiva SL, Lukkarila JL, Gunning PT..  (2013)  Exploring a new frontier in cancer treatment: targeting the ubiquitin and ubiquitin-like activating enzymes.,  56  (6): [PMID:23360215] [10.1021/jm301420b]

    Source